Clinical Research Center
Malmö, Skåne County, 20502, Sweden
Location status: Recruiting
Location contact
Anders Rosengren, MD PhD
CONTACT
Anders Rosengren, MD PhD
PRINCIPAL_INVESTIGATOR
CONTACT
NCT Number: NCT07659535
The overall aim of the study is to investigate the incidence of type 2 diabetes in individuals who have access to a digital intervention tool as compared with randomized controls during three years. The tool is based on self-affirmation theory and has large emphasis on self-reflection to enable sustainable lifestyle changes. Users get access to expert-written information about relevant health topics and interact with an LLM to promote reflection on the information.
Interested in participating?
Request Info35 year and older
All sexes
Interventional
Not applicable
Malmö, Skåne County, 20502, Sweden
Location status: Recruiting
Anders Rosengren, MD PhD
CONTACT
Anders Rosengren, MD PhD
PRINCIPAL_INVESTIGATOR
CONTACT
New scalable means to prevent type 2 diabetes is needed. AI-based large language models enable new means to support people in lifestyle changes. It is, however, important that these are coupled with serious health information.
The investigators have previously shown that the digital Livsstilsverktyget ('Lifestyle tool') developed at the University of Gothenburg leads to improved glycemic controls in patients using it regularly. To make the intervention more personal the investigators have coupled it with a large language model (LLM) to promote reflection on the expert-written content of the Lifestyle tool. Thus, participants interact with the LLM to explore a current area of interest. They then get recommendations from the LLM on relevant texts from the Lifestyle tool. These texts are written by experts (physicians, researchers). The participants go through the text and are then stimulate by the LLM to reflect on how to use the content in daily life.
This study will recruit people without type 2 diabetes, aged 35 years or older, from the general population. They will be randomly assigned to the intervention or to a control group without access to the intervention. The primary outcome is the incidence type 2 diabetes during three years. The primary variable, diagnosis of type 2 diabetes, is obtained via national health registers. Thus, no physical visits or blood sampling are required. The participants will complete the Findrisc questionnaire online at baseline to assess the risk for type 2 diabetes and enable effect analysis of individuals with different risk.
The study is an investigator-initiated single-center study conducted over three years. Technical problems are referred to a study coordinator, who also responded to requests to clarify content in a general manner without providing personal advice. Study participants are managed by their ordinary healthcare providers throughout the study.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Regular use of the digital Lifestyle tool
Time frame: 3 years
Incidence of type 2 diabetes diagnosed in routine care and reported in national clinical registers, i.e. defined as random plasma glucose >11.1 mmol/L or fasting glucose >7.0 mmol/L or HbA1C ≥6.5% compared between participants regularly using the tool and on usual care.
Contact information is provided by the study sponsor or research team.
Region Skane
Other
Personalized Study With the Lifestyle Tool
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07032844
Diabetes Mellitus, Diabetes Mellitus, Type 2
Birmingham, Alabama, United States
View Trial DetailsNCT06067399
Diabetes Mellitus, Diabetes Mellitus, Type 2
Al Khārjah, Egypt
View Trial DetailsNCT07564414
Body Weight, Diabetes Mellitus
Birmingham, Alabama, United States
View Trial DetailsNCT07622628
Diabetes Mellitus, Diabetes Mellitus Type 2
Izmir, Turkey (Türkiye)
View Trial Details